BioCardia
Biocardia Home Helix Biotherapeutic Delivery Morph Access Innovations About Us
Biocardia Enabling Biointerventional Cardiology & Redefining Vascular Access Biocardia Enabling Biointerventional Cardiology & Redefining Vascular Access
BioCardia is a biotherapeutic platform and product company based on fully developed medical device technologies.
Learn More
CORE BUSINESSES

BioCardia is engaged in two core businesses:

Helix Biotherapeutic Delivery offers a catheter system for the local delivery of cells, gene, and protein therapeutics to the heart.

Morph Access Innovations develops advanced catheter products for interventional medicine.

HELIX NEWS

March 14, 2012
BioCardia and Juventas Announce Phase II Development Program of JVS-100 delivered with the Helical Infusion System to treat Heart Failure

December 6, 2011
Two Year Follow up Safety Data on Helical Infusion System reported in December 2011 Issue of EuroIntervention

more newsmore publications

 MORPH NEWS

March 2011
AccessPro Steerable Introducer Article in March 2011 Endovascular Today by Dr. Frank Arko et al.

January 6, 2011
BioCardia elects Jay M. Moyes to Board of Directors

November 18, 2010
BioCardia Announces CE Mark Approval


more newsmore publications

 

 view Morph Certification Training Video
© 2007-2009 BioCardia, Inc. | 125 Shoreway Road, Suite B, San Carlos, CA 94070 | (800) 624-1179 | (650) 226-0120 | Fax: (650) 631-3731 |

This Site is protected by United States and international copyright and trademark laws. The contents of the Site may not be distributed, modified, reproduced, or used, in whole or in part, without the prior written consent of BioCardia. Any copies of material or other content provided through the Site must include the same copyright and other proprietary notices that appear with the material or content.